

Press Release – For immediate release

BIOLIDICS' LABORATORY PARTNER TO PROVIDE LABORATORY-DEVELOPED TEST SERVICE TO CANCER HOSPITAL IN CHINA IN CLINICAL TRIALS TO TEST STATUS OF PD-L1 IN THE ADMINISTRATION OF CANCER DRUG TREATMENTS

- **The clinical trials mark the first time that Biolidics' ClearCell® FX1 System and CTChip® FR1 biochip will be used as companion diagnostics ("CDx")**
- **Successful clinical trials could lead to the potential reimbursement of such cancer drug treatments by National Healthcare Security Administration of the People's Republic of China ("PRC") under its national basic medical insurance program**

Singapore 2 July 2019 – Biolidics Limited ("Biolidics" or the "Company"), a medical technology company with a focus on cancer diagnostic solutions, wishes to clarify that its laboratory partner, Hunan Agen Medicine Laboratory Technology Co., Ltd. ("Hunan Agen Lab"), will be providing laboratory-developed test ("LDT") service to Hunan Cancer Hospital (湖南省肿瘤医院), who has obtained approval to commence clinical trials to test the status of Programmed death-ligand 1 ("PD-L1") in the administration of cancer drug treatments. The LDTs which use Biolidics' ClearCell® FX1 System and CTChip® FR1 biochip, offered by Hunan Agen Lab, have not been approved for reimbursement at this point.

The clinical trials serve to improve patient selection to the targeted cancer drug treatment. It also aims to show the efficacy of the combination treatment and changes in circulating tumour cells ("CTCs") after administration of the cancer drug treatment, and to evaluate the correlation between PD-L1 expressions derived from CTCs and tumour tissue cells.

These clinical trials mark the first time that Biolidics' ClearCell® FX1 System and CTChip® FR1 biochip will be used as CDx, which is a diagnostic test used as a companion to a therapeutic drug to determine its applicability to a specific person. The rising focus on personalised medicine and co-development of drug and diagnostic technologies has led to the growth of the global CDx market.

Successful clinical trials could lead to the potential reimbursement of such cancer drug treatments by National Healthcare Security Administration of the PRC under its national basic medical insurance program.

Using a small amount of blood sample, the LDTs offered by Hunan Agen Lab have the potential for many applications throughout the various stages of a patient's cancer journey, such as cancer screening, cancer staging and post-cancer monitoring. The LDTs that utilise Biolidics' technology subject cancer patients to minimal invasive procedures, improve clinical outcomes and optimise cost and efficiency.

Serving various hospitals in Hunan Province including two major hospitals, Xiangya Hospital Central South University (中南大学湘雅医院) and Hunan Cancer Hospital (湖南省肿瘤医院), Hunan Agen Lab provides multidisciplinary diagnostics, including clinical cellular and molecular genetics, clinical pathology, clinical immunology, clinical biochemistry, and advanced equipment such as Next Generation Sequencing.

- END -

About Biolidics Limited

(Bloomberg Code: BLD:Singapore / Reuters Code: BIOL.SI / SGX Code: 8YY)

Incorporated in 2009, Biolidics is a Singapore-based medical technology company focusing on the development of cell enrichment systems which, when combined with other analytical tests, have a wide range of applications for cancer diagnosis, prognosis, treatment selection and treatment monitoring.

Biolidics has developed and commercialised the ClearCell® FX1 System, a fully automated CE-IVD medical device which relies on a novel patented technology to separate and enrich cancer cells from blood.

The ClearCell® FX1 System, installed across Asia, Europe and North America, allows users of the system to perform liquid biopsies to test for the presence of cancer cells (specifically circulating tumour cells, or CTCs) in blood samples or perform further analysis on cancer cells.

Liquid biopsies (i.e. analysis of the circulating tumour cells in blood samples) have many applications throughout the various stages of a patient's cancer journey, from cancer screening and staging to personalised treatment, and post- cancer monitoring.

Biolidics' quality assurance capabilities have been recognised through its ISO 13485 certification, CE-IVD, US FDA Class I registration and NMPA (formerly CFDA) Class I registration (for the MGI EasyCell System).

For additional information, please visit www.biolidics.com.

Issued on behalf of Biolidics Limited by 8PR Asia Pte Ltd.

Media & Investor Contacts:



Mr. Alex TAN
Mobile: +65 9451 5252
Email: alex.tan@8prasia.com

This press release has been prepared by Biolidics Limited (the "Company") and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist. This press release has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.